USANA Health Sciences (USNA)
(Real Time Quote from BATS)
$40.34 USD
+0.84 (2.13%)
Updated Aug 7, 2024 11:28 AM ET
5-Strong Sell of 5 5
A Value C Growth B Momentum A VGM
Brokerage Reports
USANA Health Sciences, Inc. [USNA]
Reports for Purchase
Showing records 101 - 120 ( 129 total )
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q1 EPS Upside and 2013 Guidance Increase; Maintain NEUTRAL, but Raising PT to $54
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q1 Consumer Sector Preview: Inclement Winter Weather Along with Currency Impacts to Challenge Q1 Results, Particularly for Callaway Golf
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Upgrading to NEUTRAL Due to Stronger-Than-Expected Asia Plus Recent MLM Selloff
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q3 Upside on Asia Pickup and Effect of Sales Promotion; Maintain UNDERPERFORM, but Raising PT to $40
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Short-Term Promotion Aimed at Helping Productivity and Distributor Retention; Maintain UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q1 Upside Surprise on Sales Promotion, Lower Tax Rate; Maintain UNDERPERFORM, but Raising PT to $37
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Pre-Buying Before Asia Price Increases Drives Q1 Upside; Maintain UNDERPERFORM, but Raising PT to $34
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Inline Q4 Results, but 2012 EPS Guidance Below Consensus; Lower EstImates, Maintain UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Solid Q3 Results, but Concerns over N. America Recruiting Trends Remain; Maintain UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q2 Results Relatively In Line; Accelerating North American Active Associate Decline Troublesome
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Potential Threat of Distributor Attrition to Competitive Start-Up, Led by Former Executives
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Preannounces Q2 Results Ahead of Expectations on Change to China Integration Strategy
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Solid Asia and Benefit from F/X, Partially Offset by Sluggish US Recruiting Trends
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R